The Shift in Investor Priorities: From Climate to Health
In a striking revelation from Berenberg Bank's April report, climate change has lost its perch among institutional investors' top ESG concerns. Surveying 200 institutional investors, the report found climate, previously ranked No. 1 or No. 2 for three years, now in fifth place. Health has surged to the forefront. The anonymous poll also queried alignment with United Nations Sustainable Development Goals (SDGs): only half targeted climate action (SDG 13), down sharply from 70% the prior year.
This Ozempic mania among investors reflects broader trends. PitchBook's February analysis highlighted declining venture capital in clean and climate tech for 2025, contrasted by a 26.1% rise in global health-tech funding last year over 2024. GLP-1 weight loss drugs like Ozempic (semaglutide) drive this enthusiasm, with sales soaring and oral formulations poised to expand access as affordability improves.
Understanding the GLP-1 Boom Driving Investor Interest
GLP-1 receptor agonists, such as Ozempic, mimic the glucagon-like peptide-1 hormone to regulate blood sugar, slow gastric emptying, and suppress appetite. This mechanism promotes significant weight loss—often 15-20% of body weight in clinical trials—and improves metabolic markers like insulin sensitivity. Beyond obesity, these peptides show promise in cardiovascular risk reduction and type 2 diabetes management, fueling a lucrative market projected to exceed $100 billion by 2030.
The wellness and longevity obsession amplifies this: startups offering precautionary body scans, advanced blood tests, and peptide therapies thrive. Investors see tangible profitability in health-tech, where GLP-1s demonstrably reduce food intake and long-term medical needs, as noted in Berenberg's metrics shift.
Why Climate Change Fell: Political Headwinds and Greenhushing
Climate's demotion stems from U.S. political pressures. The Trump administration slashed funding, dismantled regulations, and politicized the issue, with global ripple effects. At the IMF and World Bank spring meetings, priorities include a new climate action plan, yet Guardian reporting reveals 'greenhushing'—senior staff self-censoring climate mentions to avoid conflict.
If global institutions mute climate talk, investors follow suit. Berenberg's survey showed over 70% measuring fund impact via 'emissions avoided' in 2024-2025, dropping to just over half this year. 'Resources saved' now leads, aligning with GLP-1 benefits like lowered resource use in healthcare and nutrition.
Climate Change's Profound Health Implications
Investors chasing Ozempic mania overlook climate's direct health toll. Heatwaves don't just kill—they worsen pregnancy outcomes, mental health, asthma, sleep quality, and raise injury risks from accidents.
Vector-Borne Diseases on the Rise
Rising temperatures expand habitats for disease vectors. Dengue, chikungunya, and Lyme disease proliferate as mosquitoes and ticks thrive in warmer conditions; pathogens replicate faster too. A January Nature study projects 123 million additional malaria cases in Africa over 25 years due to climate change. Fungi may adapt, spawning new infections or enhancing existing ones like candidiasis.
Precision tracking for your journey
Join thousands using Shotlee to accurately track GLP-1 medications and side effects.
📱 Get the Shotlee App
Track your GLP-1 medications, peptides, and health metrics on the go with our mobile app!
Sea-Level Rise and Water-Related Risks
The Lancet's new commission, co-chaired by Christiana Figueres (former UN climate secretary), examines sea-level rise's health effects. As Figueres wrote in The Guardian:
'When saltwater intrudes into freshwater supplies, health suffers. When floods overwhelm sanitation systems, diseases spread. When farmland is inundated by king tides, nutrition deteriorates.'These disruptions fuel malnutrition, waterborne illnesses, and ecosystem collapse.
Climate Action's Health Benefits: A Win-Win
Prioritizing climate yields health gains. Electrifying heat and transport cuts emissions and slashes air pollution, linked to 7 million premature deaths annually per WHO estimates. Cleaner air reduces respiratory diseases, heart conditions, and cancer risks—complementary to GLP-1s' metabolic benefits.
Renewables enhance energy security; biochar improves crop yields. Framing climate investments this way could recapture investor interest without abandoning health goals.
GLP-1s in Context: Valuable but Not a Panacea
While GLP-1 drugs like Ozempic excel in obesity and metabolic health, common side effects include nausea, gastrointestinal issues, and rare risks like pancreatitis or thyroid tumors. Patients on these therapies should monitor symptoms—apps like Shotlee can track side effects or medication schedules alongside environmental exposures. However, no peptide therapy addresses systemic threats like climate-driven diseases.
Investor Guidance: Balancing Health and Climate in ESG
For ESG funds, health prioritization is valid but incomplete. Discuss with advisors integrating climate-health nexus: target SDGs holistically. Patients exploring GLP-1s for weight loss or diabetes should consult physicians on comprehensive wellness, including climate-resilient lifestyles like heat avoidance.
Comparisons underscore urgency: health-tech VC surges while climate tech lags, yet climate action prevents far more health burdens long-term.
Key Takeaways for Patients and Investors
- Berenberg survey: Climate drops to 5th in ESG; health tops list.
- GLP-1s like Ozempic drive health-tech funding up 26.1%.
- Climate health risks: Heat, diseases (123M malaria cases), sea-level threats.
- Actionable: Embrace climate in health strategies for maximal impact.
Conclusion: A Healthy Planet for True Well-Being
Investors' Ozempic mania promises profits but falters without climate. As Figueres implies, health thrives in a stable environment. ESG leaders must reconnect these dots—prioritizing both ensures a healthier future. Patients on GLP-1 therapy, consider broader factors; tools like Shotlee aid in holistic tracking.